Mochida Pharmaceutical Co., Ltd.

Yuji Kawada

Tsutomu Satoh

Fumihiko Saitoh

Hiroshi Nagasue

Provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea which are useful as bulk pharmaceutical crystals. Also provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea having excellent TrkA inhibitory effect, medicines and medicinal composition containing these crystals, and a method for producing these crystals.

Crystals of tetrahydronaphthyl urea derivative

An intermediate compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is disclosed wherein the intermediate compound is represented by formula (AM-2-RR)&#x22c5;(D-TA): in which p represents an integer of 0 to 4; Reach independently represent a halogen atom, a cyano group, a Calkyl group, a halogenated Calkyl group, a hydroxy Calkyl group, a cyanated Calkyl group, a halogenated Calkoxy group, a Calkoxy Calkyl group, a mono-/di-Calkanoyl amino group, a carboxamide group, or a Calkoxy carbonyl group; and Rand Reach independently represent a Calkyl group.

Growing community of inventors

Tokyo, Japan

Yuji Kawada